Ionis Pharmaceuticals, Inc. · NASDAQ:IONS

Ionis Pharmaceuticals — Q3 2026 Earnings Presentation

29 slides from Ionis Pharmaceuticals's earnings presentation, Nov 9, 2026

  1. Slide 1: Q3:2026 Business Update and Financial Results

    Q3:2026 Business Update and Financial Results November 9, 2026 Nasdaq: IONS 1

  2. Slide 2: On Today's Earnings Call

    On Today’s Earnings Call Brett Monia, Kyle Jenne Holly Kordasiewicz, Ph.D. Chief Global Product Beth Hougen Strategy Officer Ph.D. Chief Financial Officer Chief Executive Officer Chief Development Officer 2

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies and our expectations regarding development and re

  4. Slide 4: Introduction

    Introduction Brett Monia, Ph.D. Chief Executive Officer 4

  5. Slide 5: Positioned for Growth through Commercial Execution and Pipeline Progress

    Positioned for Growth through Commercial Execution and Pipeline Progress Expanded our Marketed Medicines1 • TRYNGOLZA for severe hypertriglyceridemia • ZANVASTRO for Alexander disease • HIBSAGO for chronic hepatitis B Reported Positive Phase 3 Data • Sefaxersen for IgA nephropathy2 • Ulefnersen for

  6. Slide 6: Accelerating Value through Commercial Execution

    Accelerating Value through Commercial Execution Kyle Jenne Chief Global Product Strategy Officer 6

  7. Slide 7: TRYNGOLZA: Launch Underway for First and Only FDA Approved Medicine in sHTG

    TRYNGOLZA: Launch Underway for First and Only FDA Approved Medicine to Reduce TGs and Risk of AP in sHTG1 Generated $41 million through Q3:20262 7 $27 Demand3 in Robust efficacy and safety • Significant and sustained triglyceride reductions $9 • Substantial reduction in acute pancreatitis events • F

  8. Slide 8: TRYNGOLZA: Establishing a New Treatment Paradigm for sHTG

    TRYNGOLZA: Establishing a New Treatment Paradigm for sHTG1 Encouraging Early Launch Fundamentals2 Strong HCP enthusiasm and intent to prescribe Demand3 Prescribing consistent with broad sHTG label in Prescribing across all expected specialties, including cardiology, endocrinology and lipidology Ceci

  9. Slide 9: Key Execution Priorities Designed to Increase and Streamline Prescribing

    Key Execution Priorities Designed to Increase and Streamline Prescribing Broaden the Prescriber Base Increasing education and engagement efforts with high-priority specialists ~1,500 HCPs have prescribed across all anticipated specialties1 1. From sHTG approval through September 30, 2026. 9

  10. Slide 10: Key Execution Priorities Designed to Increase and Streamline Prescribing

    Key Execution Priorities Designed to Increase and Streamline Prescribing Increase the Depth of Broaden the Prescriber Base Prescribing Increasing education and Help early prescribers engagement efforts with gain experience, identify high-priority specialists additional appropriate patients and expan

  11. Slide 11: Key Execution Priorities Designed to Increase and Streamline Prescribing

    Key Execution Priorities Designed to Increase and Streamline Prescribing Increase the Depth of Expand and Streamline Broaden the Prescriber Base Prescribing Access Increasing education and Help early prescribers Educate HCP offices on engagement efforts with gain experience, identify payer requireme

  12. Slide 12: TRYNGOLZA: Significant Opportunity for Underserved sHTG Patients

    Substantial Unmet Need Fasting triglycerides ≥500 mg/dL and increased risk of potentially life-threatening acute pancreatitis (AP) Limited benefit from other treatments, including fibrates TRYNGOLZA: and omega-3s Significant Opportunity for Underserved sHTG Significant Market Opportunity1 Patients >

  13. Slide 13: DAWNZERA Launch Continues to Gain Momentum

    DAWNZERA Launch Continues to Gain Momentum1 Delivering on What HAE Patients Need Most First and Only RNA-Targeted Treatment to Prevent HAE Attacks Generated $79 million through Q3:2026 Indicated for prophylaxis to prevent attacks of HAE in adult and pediatric patients ≥12 years old $37 $26 • Prescri

  14. Slide 14: NOW APPROVED

    NOW APPROVED The first and only disease-modifying therapy approved by the FDA for the treatment of pediatric and adult patients with Alexander disease1 1. See Full ZANVASTRO Prescribing Information.

  15. Slide 15: ZANVASTRO: Ionis' First Independent Neurology Launch

    Substantial Unmet Need Alexander disease (AxD): An ultra-rare, progressive and often fatal neurological disorder First approved disease-modifying treatment Broad Label ZANVASTRO: Enables treatment for children and adults with AxD Ionis’ First Independent Early Enthusiasm from AxD Community Neurology

  16. Slide 16: Clear Commercial Priorities Across Launches

    Clear Commercial Priorities Across Launches First Broad Patient HAE Launch Driving First Independent Population Launch Commercial Neurology Launch Underway Revenue Growth Underway Convert HCP enthusiasm Continue building Help HCPs initiate into broader, repeat momentum across all treatment for patie

  17. Slide 17: Delivering Important Pipeline Achievements

    Delivering Important Pipeline Achievements Holly Kordasiewicz, Ph.D. Chief Development Officer 17

  18. Slide 18: TRYNGOLZA: First and Only FDA Approved Medicine to Reduce TGs and Risk of AP in sHTG

    TRYNGOLZA: First and Only FDA Approved Medicine to Reduce TGs and Risk of AP in sHTG Reductions in Fasting Triglycerides Up to 72% placebo-adjusted mean reduction1 at 6 months Up to 79% mean reduction2 in up to 2 years (p<0.0001) Phase 3 placebo-controlled data Open-label extension data Reduction in

  19. Slide 19: ZANVASTRO: Ionis' First Independent Launch from Leading Neurology Pipeline

    ZANVASTRO: Ionis’ First Independent Launch from Leading 1 Neurology Pipeline ZANVASTRO for the treatment of Alexander disease First and only disease modifying treatment approved for Alexander disease Positive pivotal study data: ambulatory status • Statistically significant stabilization of motor fu

  20. Slide 20: Obudanersen: A Promising Investigational Medicine for Angelman Syndrome

    Obudanersen: A Promising Investigational Medicine for Angelman Syndrome • >100k people in major geographies with Angelman syndrome, The a severe, rare neurodevelopmental disorder1 Opportunity • Significant unmet need with no approved disease-modifying treatments • Positive results seen in the HALOS

  21. Slide 21: Partnered Medicines Amplify Our Opportunities

    Partnered Medicines Amplify Our Opportunities1 HIBSAGOTM Sefaxersen Ulefnersen (CHB)3 (IgAN) (FUS-ALS) Program Approved in the U.S., Japan Positive interim Phase 3 Positive topline Phase 3 and Canada; Under data; Potential 2027 U.S. data; Potential 2027 U.S. Status regulatory review in approval1 app

  22. Slide 22: 2026 Progress and First Look at 2027 Key Value-Driving Events

    2026 Progress and First Look at 2027 Key Value-Driving Events1 Phase 3 Clinical Events Regulatory Actions Product Launches 2026 2026 2026 Phase 2 HIBSAGO Pelacarsen Phase 2 Phase 2 DAWNZERA B-Well data DAWNZERA Clinical (CHB) Data Events Lp(a) HORIZON data Clinical DataTRYNGOLZA Events ZANVASTRO Cli

  23. Slide 23: Q3:2026 Financial Performance

    Q3:2026 Financial Performance Beth Hougen Chief Financial Officer 23

  24. Slide 24: Q3:2026 YTD Financial Highlights

    Q3:2026 YTD Financial Highlights1 Commercial Revenue: $363M R&D Revenue: $394M Revenues ▪ $41M in TRYNGOLZA product sales ▪ Significant YoY increase driven $757M ▪ $79M in DAWNZERA product sales by multiple payments as ▪ 23% increase year-over-year (YoY) partnered programs advance3 R&D Expenses2: $5

  25. Slide 25: Reaffirming 2026 Total Revenue, Operating Loss and Cash Guidance

    Reaffirming 2026 Total Revenue, Operating Loss and Cash Guidance1,2 Revenue Operating Loss Cash $875-900M $425-475M2 >$1.6B TRYNGOLZA net product sales ~$50M (lowered from $100-110M) Reflects strong revenue Supports investments in generation from multiple launches, DAWNZERA net product sales sources

  26. Slide 26: Conclusion

    Conclusion Brett Monia, Ph.D. Chief Executive Officer 26

  27. Slide 27: Driving Accelerating Growth

    Driving Accelerating Growth1 Rich, Advancing Steady Cadence of Accelerating Driving Toward Pipeline New Medicines Revenue Growth Sustained Positive Cash Flow 1. Based on current estimates, subject to change. 27

  28. Slide 28: Q&A

    Q&A IONIS

  29. Slide 29: Breakthrough Therapies Driving Accelerating Growth

    Breakthrough Therapies Driving Accelerating Growth 29

Ionis Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix